ReviewRespiratory research2010
Clinical use of biomarkers of survival in pulmonary fibrosis.
Review in Respiratory research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Benefits of different characteristics of pulmonary rehabilitation programs in patients with interstitial lung disease: a systematic review and meta-analysis.Annals of medicine · 2025Pooled it
- Prognostic value of [Scientific reports · 2025Article
- The Challenging Diagnosis of Interstitial Lung Disease in Children-One Case Report and Literature Review.Journal of clinical medicine · 2022Article
- Pulmonary long-term consequences of COVID-19 infections after hospital discharge.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2021Article
- Predictors of short-term LAMA ineffectiveness in treatment naïve patients with moderate to severe COPD.Wiener klinische Wochenschrift · 2018Article
- A functional genomic model for predicting prognosis in idiopathic pulmonary fibrosis.BMC pulmonary medicine · 2015Article
- A novel genomic signature with translational significance for human idiopathic pulmonary fibrosis.American journal of respiratory cell and molecular biology · 2015Article
- Differences in serum SP-D levels between German and Japanese subjects are associated with SFTPD gene polymorphisms.BMC medical genetics · 2014Article
- Idiopathic pulmonary fibrosis: the need for early diagnosis.Multidisciplinary respiratory medicine · 2013Article
- Noninvasive monitoring of pulmonary fibrosis by targeting matrix metalloproteinases (MMPs).Molecular pharmaceutics · 2013Article
- Idiopathic pulmonary fibrosis: current challenges and future perspectives.European respiratory review : an official journal of the European Respiratory Society · 2013Article
- Article
- Serological investigation of the collagen degradation profile of patients with chronic obstructive pulmonary disease or idiopathic pulmonary fibrosis.Biomarker insights · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBiologic predictors or biomarkers of survival in pulmonary fibrosis with a worse prognosis, more specifically in idiopathic pulmonary fibrosis would help the clinician in deciding whether or not to treat since treatment carries a potential risk for adverse events. These decisions are made easier if accurate and objective measurements of the patients' clinical status can predict the risk of progression to death.
methodA literature review is given on different biomarkers of survival in interstitial lung disease, mainly in IPF, since this disease has the worst prognosis.
conclusionSerum biomarkers, and markers measured by medical imaging as HRCT, pertechnegas, DTPA en FDG-PET are not ready for clinical use to predict mortality in different forms of ILD. A baseline FVC, a change of FVC of more than 10%, and change in 6MWD are clinically helpful predictors of survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.